TYRATyra Biosciences, Inc.

1. Sep 15, 2026On September 14, 2026, Tyra Biosciences, Inc. (TYRA or the Company) entered into an underwriting agreement (the Underwriting Agreement) with Jefferies LLC, Guggenheim Securities, LLC, Cantor Fitzgerald & Co. and Barclays Capital Inc., as representatives of the several underwriters named therein (collectively, the …Other event · Form 8-K
2. Sep 9, 2026On September 9, 2026, Tyra Biosciences, Inc. (TYRA or the Company) announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with Fibroblast Growth Factor Receptor (FGFR) 3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC)Other event · Form 8-K
3. Aug 4, 2026Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights.Earnings release · press release
4. May 13, 2026Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights.Earnings release · press release
5. Apr 17, 2026On April 16, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the board of directors (the Board) of Tyra Biosciences, Inc. (the Company), and pursuant to the amended and restated bylaws of the Company, the Board approved an increase in the number of authorized directors from nine …Director or officer change · Form 8-K
6. Apr 2, 2026On April 1, 2026, the Board of Directors of Tyra Biosciences, Inc. (the Company) designated Julia Rueb, Vice President, Finance of the Company, as the Company’s principal accounting officer, succeeding Alan Fuhrman, the Company’s Chief Financial Officer, in that role, each effective as of April 1, 2026.Director or officer change · Form 8-K
7. Mar 4, 2026On March 4, 2026, Tyra Biosciences, Inc. (the “Company”) agreed to issue and sell 4,000,000 shares of common stock to a large investment management firm at a purchase price of $31.50 per share.Other event · Form 8-K
8. Mar 2, 2026Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights.Earnings release · press release
9. Dec 1, 2025On November 25, 2025, the Board of Directors (the Board) of Tyra Biosciences, Inc. (the Company) appointed Bhavesh Ashar as the Company’s Chief Operating Officer, succeeding Daniel Bensen in that position, who was appointed the Company’s Chief Discovery Officer, each effective as of December 1, 2025.Director or officer change · Form 8-K
10. Nov 5, 2025Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.